CGT6297
Phase 1Small molecule
CGT6297 is one of 4 small molecule programs targeting PIK3CA Mutation. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in PIK3CA Mutation
#DrugCompanyPhaseTrials
1Truqap
AstraZenecaPhase 3
Faslodex
FFresenius Kabi Oncology Ltd.
Phase 3
RLY-2608
Relay TherapeuticsPhase 3
CGT6297
CCogent Biosciences, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CGT6297. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCogent Biosciences, Inc.